Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

Expert Opinion on Investigational Drugs - Tập 26 Số 6 - Trang 735-739 - 2017
Dev Mehta1, Robert Jackson1, Gaurav Paul1, Jiong Shi1, Marwan N. Sabbagh1
1Alzheimer’s and Memory Disorders Division, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.3233/JAD-2008-15213

10.3233/JAD-2007-12105

10.2174/156720508785132299

10.2174/156720507781788828

10.1186/s13195-016-0189-7

10.1056/NEJMoa1304839

10.1056/NEJMoa1312889

10.1016/j.jalz.2015.06.1893

10.1126/science.337.6096.790

Bezprozvanny I, 2010, Drug News Perspect, 23, 518, 10.1358/dnp.2010.23.8.1500435

10.1016/j.jalz.2015.08.152

10.1016/j.jalz.2015.08.153

10.1001/archneurol.2012.2194

10.1056/NEJMoa1210951

10.1016/j.bcp.2012.11.014

10.1097/NEN.0b013e31825018f7

10.1016/j.jalz.2014.04.450

10.1001/archneurol.2011.1538

10.3233/JAD-2008-15312

10.1056/NEJM199210293271801

10.1176/ajp.141.11.1356

Connor DJ, 1998, Administration Manual for the Alzheimer’s Disease Assessment Scale

10.2174/156720510793499075

Thông tin
Thông tin xuất bản

Expert Opinion on Investigational Drugs

Tập 26 Số 6

735-739

Thông tin tác giả